Thursday, September 5, 2013
Although many long noncoding RNAs are upregulated in cancer,
relatively few have been shown to functionally contribute to disease.1
Now, a U.S. team has found that two lncRNAs act directly on the androgen receptor and are
required for castration-resistant prostate cancer growth. The findings provide
new targets for the disease and illustrate a previously unknown mechanism of
action for lncRNAs.2
C. SciBX 6(34);
Published online Sept. 5, 2013
1. Wahlestedt, C. Nat.
Rev. Drug. Discov. 12, 433-446 (2013)
2. Yang, L. et al.
Nature; published online Aug. 14, 2013;
Contact: Michael G. Rosenfeld, University of California, San Diego,
La Jolla, Calif.
Contact: Chunru Lin, The University of Texas MD Anderson Cancer Center,
Contact: Liuqing Yang, same affiliation as above
3. Prensner, J.R. &
Chinnaiyan, A.M. Cancer Discov. 1, 391-407 (2011)
4. Brunner, A.L. et al.
Genome Biol. 13, R75 (2012)
5. Hung, T. et al. Nat.
Genet. 43, 621-629 (2011)
6. Schmitt, A.M. &
Chang, H.Y. Nature 500, 536-537 (2013)
AND INSTITUTIONS MENTIONED
Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), Bridgewater, N.J.
Hologic Inc. (NASDAQ:HOLX), Bedford, Mass.
Howard Hughes Medical Institute, Chevy Chase, Md.
RaNA Therapeutics Inc., Cambridge, Mass.
Santaris Pharma A/S, Horsholm, Denmark
Stanford University School of Medicine, Stanford, Calif.
University of California, San Diego, La Jolla, Calif.
University of Miami Miller School of Medicine, Miami, Fla.
The University of Texas MD Anderson Cancer Center, Houston, Texas